NLS Pharmaceutics Ownership 2024 | Who Owns NLS Pharmaceutics Now?
Institutional Ownership
22.34%
Insider Ownership
26.62%
Retail Ownership
51.04%
Institutional Holders
9.00
NLS Pharmaceutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BVF INC/IL | 15.05% | 0.03% | 5,747,126 | - | - | 1,246,552 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 6.05% | 0.01% | 2,311,000 | 139,000 | 6.40% | 501,256 | Jun 30, 2024 |
| UBS GROUP AG | 0.62% | - | 235,723 | 235,723 | 100.00% | 51,152 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.06% | - | 21,777 | -157,800 | -87.87% | 4,723 | Jun 30, 2024 |
| HRT FINANCIAL LP | 0.04% | - | 16,832 | 16,832 | 100.00% | 3,000 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.04% | - | 14,362 | - | - | 3,115 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.00% | - | 90 | - | - | 19 | Jun 30, 2024 |
| XTX TOPCO LTD | - | - | - | -25,594 | -100.00% | - | Jun 30, 2024 |
NLS Pharmaceutics's largest institutional shareholder is BVF INC/IL, holding 15.05% of the company's total share outstanding, currently valued at $1.25M. The top 10 institutional shareholders own together 21.86% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BVF INC/IL | 15.05% | 0.03% | 5,747,126 | - | - | 1,246,552 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 6.05% | 0.01% | 2,311,000 | 139,000 | 6.40% | 501,256 | Jun 30, 2024 |
| HRT FINANCIAL LP | 0.04% | - | 16,832 | 16,832 | 100.00% | 3,000 | Jun 30, 2024 |
| UBS GROUP AG | 0.62% | - | 235,723 | 235,723 | 100.00% | 51,152 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.06% | - | 21,777 | -157,800 | -87.87% | 4,723 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.04% | - | 14,362 | - | - | 3,115 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.00% | - | 90 | - | - | 19 | Jun 30, 2024 |
| XTX TOPCO LTD | - | - | - | -25,594 | -100.00% | - | Jun 30, 2024 |
The largest NLS Pharmaceutics shareholder by % of total assets is BVF INC/IL. The company owns 5.75M shares of NLS Pharmaceutics (NLSP), representing 0.03% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| UBS GROUP AG | 0.62% | - | 235,723 | 235,723 | 100.00% | 51,152 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 6.05% | 0.01% | 2,311,000 | 139,000 | 6.40% | 501,256 | Jun 30, 2024 |
| HRT FINANCIAL LP | 0.04% | - | 16,832 | 16,832 | 100.00% | 3,000 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.00% | - | 90 | - | - | 19 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.04% | - | 14,362 | - | - | 3,115 | Jun 30, 2024 |
| BVF INC/IL | 15.05% | 0.03% | 5,747,126 | - | - | 1,246,552 | Jun 30, 2024 |
| XTX TOPCO LTD | - | - | - | -25,594 | -100.00% | - | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.06% | - | 21,777 | -157,800 | -87.87% | 4,723 | Jun 30, 2024 |
As of Jun 30 2024, NLS Pharmaceutics's largest institutional buyer is UBS GROUP AG. The company purchased 235.72K stocks of NLSP, valued at $51.15K.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 0.06% | - | 21,777 | -157,800 | -87.87% | 4,723 | Jun 30, 2024 |
| XTX TOPCO LTD | - | - | - | -25,594 | -100.00% | - | Jun 30, 2024 |
| BVF INC/IL | 15.05% | 0.03% | 5,747,126 | - | - | 1,246,552 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.04% | - | 14,362 | - | - | 3,115 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.00% | - | 90 | - | - | 19 | Jun 30, 2024 |
| HRT FINANCIAL LP | 0.04% | - | 16,832 | 16,832 | 100.00% | 3,000 | Jun 30, 2024 |
| ARMISTICE CAPITAL, LLC | 6.05% | 0.01% | 2,311,000 | 139,000 | 6.40% | 501,256 | Jun 30, 2024 |
| UBS GROUP AG | 0.62% | - | 235,723 | 235,723 | 100.00% | 51,152 | Jun 30, 2024 |
As of Jun 30 2024, NLS Pharmaceutics's biggest institutional seller is RENAISSANCE TECHNOLOGIES LLC. The company sold -0.16M shares of NLSP, valued at $4.72K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| UBS GROUP AG | 0.62% | - | 235,723 | 235,723 | 100.00% | 51,152 | Jun 30, 2024 |
| HRT FINANCIAL LP | 0.04% | - | 16,832 | 16,832 | 100.00% | 3,000 | Jun 30, 2024 |
NLS Pharmaceutics's largest new institutional shareholder by number of shares is UBS GROUP AG, purchased 235.72K shares, valued at $51.15K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| XTX TOPCO LTD | - | - | - | -25,594 | -100.00% | - | Jun 30, 2024 |
NLS Pharmaceutics's largest sold out institutional shareholder by shares sold is XTX TOPCO LTD, sold -25.59K shares, valued at -, as of undefined.
NLS Pharmaceutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 9 | 28.57% |
| 31 Mar, 24 | 7 | 40.00% |
| 31 Dec, 23 | 5 | -28.57% |
| 30 Sep, 23 | 7 | -22.22% |
| 30 Jun, 23 | 9 | 28.57% |
| 31 Mar, 23 | 7 | 75.00% |
| 31 Dec, 22 | 4 | - |
| 30 Sep, 22 | 4 | - |
| 30 Jun, 22 | 4 | -20.00% |
| 31 Mar, 22 | 5 | -28.57% |
| 31 Dec, 21 | 7 | 40.00% |
| 30 Sep, 21 | 5 | 25.00% |
| 30 Jun, 21 | 4 | - |
| 31 Mar, 21 | 4 | - |
As of 30 Jun 24, 9 institutions are holding NLS Pharmaceutics's shares, representing an increase of 28.57% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 8,526,852 | 4.52% |
| 31 Mar, 24 | 8,157,932 | 39.91% |
| 31 Dec, 23 | 5,830,804 | -7.36% |
| 30 Sep, 23 | 6,294,283 | -2.58% |
| 30 Jun, 23 | 6,461,209 | 1.50% |
| 31 Mar, 23 | 6,365,941 | 9.92% |
| 31 Dec, 22 | 5,791,528 | 4924.18% |
| 30 Sep, 22 | 115,273 | -90.89% |
| 30 Jun, 22 | 1,266,025 | 1659.81% |
| 31 Mar, 22 | 71,941 | -45.19% |
| 31 Dec, 21 | 131,248 | -2.58% |
| 30 Sep, 21 | 134,723 | 106.41% |
| 30 Jun, 21 | 65,270 | -52.72% |
| 31 Mar, 21 | 138,038 | - |
NLS Pharmaceutics (NLSP) has 8.53M shares outstanding as of 30 Jun 24, up 4.52% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 22.34% | 4.89% |
| 31 Mar, 24 | 21.37% | 9.16% |
| 31 Dec, 23 | 15.27% | 0.55% |
| 30 Sep, 23 | 52.89% | 1.79% |
| 30 Jun, 23 | 54.29% | 1.90% |
| 31 Mar, 23 | 53.49% | 2.26% |
| 31 Dec, 22 | 48.66% | 5187.59% |
| 30 Sep, 22 | 0.97% | 0.86% |
| 30 Jun, 22 | 10.64% | 2911.18% |
| 31 Mar, 22 | 0.60% | 49.70% |
| 31 Dec, 21 | 1.10% | 86.06% |
| 30 Sep, 21 | 1.13% | 376.39% |
| 30 Jun, 21 | 0.55% | 40.77% |
| 31 Mar, 21 | 1.16% | - |
As of 30 Jun 24, NLS Pharmaceutics is held by 22.34% institutional shareholders, representing a 4.89% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 5 | 25.00% |
| 31 Mar, 24 | 4 | - |
| 31 Dec, 23 | - | -100.00% |
| 30 Sep, 23 | 2 | -60.00% |
| 30 Jun, 23 | 5 | - |
| 31 Mar, 23 | 5 | 150.00% |
| 31 Dec, 22 | 2 | -33.33% |
| 30 Sep, 22 | 3 | 50.00% |
| 30 Jun, 22 | 2 | -33.33% |
| 31 Mar, 22 | 3 | -25.00% |
| 31 Dec, 21 | 4 | -20.00% |
| 30 Sep, 21 | 5 | 25.00% |
| 30 Jun, 21 | 4 | - |
| 31 Mar, 21 | 4 | - |
5 institutional shareholders have increased their position in NLSP stock as of 30 Jun 24 compared to 4 in the previous quarter (a 25.00% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 1 | - |
| 31 Mar, 24 | - | -100.00% |
| 31 Dec, 23 | 1 | -50.00% |
| 30 Sep, 23 | 2 | 100.00% |
| 30 Jun, 23 | 1 | - |
| 31 Mar, 23 | - | -100.00% |
| 31 Dec, 22 | 1 | - |
| 30 Sep, 22 | - | -100.00% |
| 30 Jun, 22 | 1 | - |
| 31 Mar, 22 | 1 | -50.00% |
| 31 Dec, 21 | 2 | - |
| 30 Sep, 21 | - | - |
| 30 Jun, 21 | - | - |
| 31 Mar, 21 | - | - |
1 institutional shareholders have reduced their position in NLSP stock as of 30 Jun 24 compared to - in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 9 | 28.57% | 8,526,852 | 4.52% | 22.34% | 4.89% | 5 | 25.00% | 1 | - |
| 31 Mar, 24 | 7 | 40.00% | 8,157,932 | 39.91% | 21.37% | 9.16% | 4 | - | - | -100.00% |
| 31 Dec, 23 | 5 | -28.57% | 5,830,804 | -7.36% | 15.27% | 0.55% | - | -100.00% | 1 | -50.00% |
| 30 Sep, 23 | 7 | -22.22% | 6,294,283 | -2.58% | 52.89% | 1.79% | 2 | -60.00% | 2 | 100.00% |
| 30 Jun, 23 | 9 | 28.57% | 6,461,209 | 1.50% | 54.29% | 1.90% | 5 | - | 1 | - |
| 31 Mar, 23 | 7 | 75.00% | 6,365,941 | 9.92% | 53.49% | 2.26% | 5 | 150.00% | - | -100.00% |
| 31 Dec, 22 | 4 | - | 5,791,528 | 4924.18% | 48.66% | 5187.59% | 2 | -33.33% | 1 | - |
| 30 Sep, 22 | 4 | - | 115,273 | -90.89% | 0.97% | 0.86% | 3 | 50.00% | - | -100.00% |
| 30 Jun, 22 | 4 | -20.00% | 1,266,025 | 1659.81% | 10.64% | 2911.18% | 2 | -33.33% | 1 | - |
| 31 Mar, 22 | 5 | -28.57% | 71,941 | -45.19% | 0.60% | 49.70% | 3 | -25.00% | 1 | -50.00% |
| 31 Dec, 21 | 7 | 40.00% | 131,248 | -2.58% | 1.10% | 86.06% | 4 | -20.00% | 2 | - |
| 30 Sep, 21 | 5 | 25.00% | 134,723 | 106.41% | 1.13% | 376.39% | 5 | 25.00% | - | - |
| 30 Jun, 21 | 4 | - | 65,270 | -52.72% | 0.55% | 40.77% | 4 | - | - | - |
| 31 Mar, 21 | 4 | - | 138,038 | - | 1.16% | - | 4 | - | - | - |
NLS Pharmaceutics Peer Ownership
| Ticker | Company |
|---|---|
| ACHL | Achilles Therapeutics plc |
| LIXT | Lixte Biotechnology Holdings, Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| CTMX | CytomX Therapeutics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| HCWB | HCW Biologics Inc. |
| ASMB | Assembly Biosciences, Inc. |
| RZLT | Rezolute, Inc. |
| INDP | Indaptus Therapeutics, Inc. |
| NRBO | NeuroBo Pharmaceuticals, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| PTIX | Protagenic Therapeutics, Inc. |
| NLTX | Neurogene Inc. |
| TIL | Instil Bio, Inc. |
| ELYM | Eliem Therapeutics, Inc. |
NLSP Ownership FAQ
Who Owns NLS Pharmaceutics?
NLS Pharmaceutics is owned by institutional shareholders (22.34%), insiders (26.62%), and public (51.04%). The largest institutional shareholder of NLS Pharmaceutics is BVF INC/IL (15.05% of total shares) and the top mutual fund owner is (0% of total shares).
Who are the major institutional shareholders of NLS Pharmaceutics?
NLS Pharmaceutics's major institutional shareholders are BVF INC/IL, ARMISTICE CAPITAL, LLC, UBS GROUP AG, RENAISSANCE TECHNOLOGIES LLC, and HRT FINANCIAL LP. The top five shareholders own together 21.83% of the company's share outstanding.
How many NLS Pharmaceutics shareholders are there?
As of Jun 2024, there are 9 institutional shareholders of NLS Pharmaceutics.
What percentage of NLS Pharmaceutics is owned by BVF INC/IL?
BVF INC/IL owns 5.75M shares of NLS Pharmaceutics, representing 15.05% of the company's total shares outstanding, valued at $1.25M (as of Jun 2024).
What percentage of NLS Pharmaceutics is owned by ARMISTICE CAPITAL, LLC?
As of Jun 2024, ARMISTICE CAPITAL, LLC holds 2.31M shares of NLS Pharmaceutics (NLSP), compromising 6.05% of the company, valued at $501.26K.
What percentage of NLS Pharmaceutics is owned by UBS GROUP AG?
UBS GROUP AG is the third largest holder of NLS Pharmaceutics. The company owns 235.72K of the company's shares outstanding (worth $51.15K).